About: Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease
Creator	Campbell-Lee, Sally Gowhari, Michel Jain, Shivi Khan, Irum Koshy, Matthew Mahmud, Nadim Peace, David Rondelli, Damiano Sweiss, Karen Gordeuk, Victor Molokie, Robert Oh, Annie Patel, Pritesh Quigley, John Saraf, Santosh
Source	Elsevier; Medline; PMC
abstract	We report on the screening and development of haploidentical hematopoietic stem cell transplantation (HSCT) for adult patients with clinically aggressive sickle cell disease (SCD) at our institution. Of 50 adult SCD patients referred for HSCT between January 2014 and March 2017, 20% were denied by insurance. Of 41 patients initially screened, 10% lacked an available haploidentical donor, 29% had elevated donor-specific antibodies (DSAs), and 34% declined to proceed to HSCT. All 10 patients who were transplanted received peripheral blood stem cells. The initial 2 were conditioned with alemtuzumab/total body irradiation (TBI) 3 Gy followed by post-transplant cyclophosphamide and failed to engraft. The next 8 patients received the regimen developed at Johns Hopkins University with TBI 3 Gy. Granulocyte colony-stimulating factor was administered from day +12 in those with HbS < 30%. All 8 patients engrafted with a median time to neutrophil >.5 × 10(9)/L of 22 days (range, 18 to 23). One patient subsequently lost the graft, and 7 (87.5%) maintained >95% donor cell chimerism at 1-year post-HSCT. Two patients developed acute graft-versus-host disease (GVHD) of at least grade II. One had chronic GVHD and died >1 year after HSCT of unknown causes. With a median follow-up of 16 months (range, 11 to 29), 7 patients (87.5%) are alive. Our findings suggest that limited insurance coverage, high rate of DSAs, and patient declining HSCT may limit the availability of haploidentical HSCT in adult SCD patients. The modified Hopkins regimen used here demonstrates high engraftment and low morbidity rates and should be tested in larger, multicenter, prospective clinical trials.
has issue date	2018-04-12(xsd:dateTime)
bibo:doi	10.1016/j.bbmt.2018.03.031
bibo:pmid	29656137
has license	no-cc
sha1sum (hex)	200b85eea010e695ac7281e5b8758c9fbbd6d0ad
schema:url	https://doi.org/10.1016/j.bbmt.2018.03.031
resource representing a document's title	Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease
has PubMed Central identifier	PMC6108914
has PubMed identifier	29656137
schema:publication	Biol Blood Marrow Transplant
resource representing a document's body	covid:200b85eea010e695ac7281e5b8758c9fbbd6d0ad#body_text
is schema:about of	named entity 'AGGRESSIVE' named entity 'Our' named entity 'cell' named entity 'All' named entity 'proceed' named entity 'availability' named entity 'range' named entity 'patients' named entity 'Sickle Cell Disease' named entity 'Stable' named entity 'ADULTS' named entity 'ENGRAFTMENT' named entity 'INITIALLY' named entity 'FOLLOW-UP' named entity 'HERE' named entity 'DENIED' named entity 'GRAFT' named entity '2887' named entity 'CYCLOPHOSPHAMIDE' named entity 'LIMIT' named entity 'DONOR CELL' named entity 'DAYS' named entity 'YEAR' named entity 'MORBIDITY' named entity 'ACUTE GRAFT-VERSUS-HOST DISEASE' named entity 'ELEVATED' named entity 'REGIMEN' covid:arg/200b85eea010e695ac7281e5b8758c9fbbd6d0ad named entity 'REPORT' named entity 'LOST' named entity 'ADULT' named entity 'SCD' named entity 'FAILED' named entity 'AVAILABILITY OF' named entity 'CLINICAL TRIALS' named entity 'HAPLOIDENTICAL DONOR' named entity 'PERIPHERAL BLOOD STEM CELL TRANSPLANTATION' named entity 'DEVELOPMENT' named entity 'SICKLE CELL DISEASE' named entity 'OUR' named entity 'INSTITUTION' named entity 'STABLE' named entity 'SCREENING' named entity 'HAPLOIDENTICAL' named entity 'HEMATOPOIETIC STEM CELL TRANSPLANTATION' named entity 'CONDITIONED' named entity 'UNKNOWN' named entity 'DECLINING' named entity 'INSURANCE COVERAGE' named entity 'INSURANCE' named entity 'TIME' named entity 'BODY' named entity '2B12' named entity 'FOLLOWED BY' named entity 'HIGH' named entity 'RATES' named entity 'HIGH RATE' named entity 'HSCT' named entity '30%' named entity 'CAUSES' named entity 'LOW' named entity 'TRANSPLANTED' named entity 'PATIENTS' named entity 'SUGGEST' named entity 'GRANULOCYTE COLONY-STIMULATING FACTOR' named entity 'POST-TRANSPLANT' named entity 'FINDINGS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software